Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 94

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 94
---
 cost ranging from ~$1,540 to $3,000 depending   
 on the number of injections required. The exact dosage regimen and treatment duration remain 
 to be determined during the planned clinical trials.                                         |

| - | Assumed average pricing per course 
 for illustration purposes: ~$2,200 |

<div align='center'>59</div>

U.S. incidence of MRSA:

| - | Based on an estimated 32 invasive                                                        
 MRSA cases per 100,000 people [10], the U.S. (population ~330 million) has approximately 
 106,000 such cases annually                                                              |

| - | U.S. Total Addressable Market TAM for invasive infections: |

| - | 106,000 × $2,200 = ~$230 million/year |

| - | Estimated annual revenue potential at 30% assumed realistic                        
 market penetration over 5 years (U.S. Serviceable Obtainable Market): ~$70 million |

Global Total Addressable Market (TAM) assumptions rationale:

| - | We estimate the global market at roughly 3 times the size of 
 the U.S. market at around $690 million.                      |

| - | Estimated global annual realistic revenue potential at 20%                               
 market penetration, which represents serviceable obtainable market (SOM): ~$130+ million |

Based on the epidemiological data and pricing
assumptions outlined above, the following table summarizes our estimates for the total addressable market (TAM) and serviceable obtainable
market (SOM) for liposomal mupirocin.

Prospective Market Opportunity Summary with Detailed Assumptions and Limitations

| Parameter                    |     | Resistant                                                                                                                              
 Gonorrhea                                                                                                                              |     | Invasive                                                  
 MRSA                                                      |
| U.S. Annual Cases            |     | ~91,000 ceftriaxone-resistant infections 5% of 710,000                                                                                 
 total U.S. Gonorrhea cases                                                                                                             |     | ~106,000 invasive MRSA infections 32/100,000 ×            
 330M population                                           |
| Estimated Cost per Treatment |     | ~$600                                                                                                                                  |     | ~$2,200                                                   |
| U.S. TAM                     |     | ~$55M 91,000 cases × $600 per treatment cost                                                                                           |     | ~$230M ~106,000 cases × $2,200 per course of              
 treatment                                                 |
| Global Multiplier            |     | 4